Top-Quality Dutasteride Powder For Hair Loss CAS:164656-23-9

    What Is Dutasteride Powder?

    Dutasteride is a synthetic 4-azasteroid compound that functions as a selective, competitive inhibitor of both type-1 and type-2 isoforms of the 5-alpha-reductase enzyme. Originally developed by Glaxo Wellcome (now GSK) and approved by the FDA in November 2001 for benign prostatic hyperplasia (BPH) at a dose of 0.5 mg under the brand name Avodart, the drug was subsequently investigated for androgenetic alopecia.

    In its raw powder form-distinct from the commercial softgel capsules-dutasteride presents as an off-white to pale yellow crystalline powder. This form is primarily utilized by compounding pharmacies for the preparation of customized topical solutions, or by researchers and individuals engaging in precise dose manipulation. The powder form offers greater flexibility in dosing and administration route compared to the fixed 0.5 mg oral capsules, though it requires careful handling and accurate measurement.

    Dutasteride has received regulatory approval for treating androgenetic alopecia in South Korea (2009), Japan (2015), and Taiwan. In the United States, United Kingdom, and most other Western countries, its use for hair loss remains "off-label"-meaning physicians may prescribe it, but the manufacturer has not pursued FDA approval for this indication.

 

    The pharmacological distinction between dutasteride and finasteride lies in their enzyme specificity. Finasteride selectively inhibits the type-2 isoform of 5-alpha-reductase. Dutasteride, by contrast, inhibits both type-1 and type-2 isoforms. This is not a trivial difference-the type-1 enzyme is expressed in the sebaceous glands, liver, and skin, while type-2 predominates in the prostate, hair follicles, and genital tissues. By targeting both, dutasteride achieves a more comprehensive suppression of DHT production.

    The clinical consequence is substantial: oral dutasteride at 0.5 mg daily reduces serum DHT levels by approximately 90-98%, compared to roughly 70-71% with finasteride. Scalp DHT reduction is similarly pronounced. This near-total DHT suppression is the primary mechanism by which dutasteride halts follicular miniaturization, allows miniaturized follicles to recover, and promotes the regrowth of thicker, healthier hair.

    Importantly, dutasteride is not an anti-androgen in the traditional sense-it does not block androgen receptors or displace DHT from its binding sites. Rather, it functions as an androgen modulator, reducing the production of DHT while leaving testosterone levels to rise as a compensatory response.

    Dutasteride powder is indicated for men with androgenetic alopecia-the hereditary, progressive thinning that follows a characteristic pattern of recession at the temples and thinning at the crown. It is not effective for other forms of hair loss such as telogen effluvium, alopecia areata, or scarring alopecias, as these conditions arise from mechanisms unrelated to DHT.

    Clinical practice typically reserves dutasteride for cases where finasteride has proven insufficient, or where hair loss is moderate to advanced rather than very early and mild. More than a third of hair transplant surgeons report that they always or often recommend dutasteride to their patients.

    Dutasteride is contraindicated in women, particularly those who are pregnant or may become pregnant, due to the risk of abnormal development of external genitalia in male fetuses. Men attempting to conceive should also exercise caution, as small amounts may be transferred in semen. Other contraindications include known hypersensitivity to dutasteride, liver disease, and elevated risk of prostate cancer.

    The evidence supporting dutasteride's efficacy is robust. A multicenter retrospective chart review of 600 men with androgenetic alopecia demonstrated that dutasteride 0.5 mg daily was superior to finasteride 1 mg daily in improving hair loss, with a comparable adverse event profile. A randomized, placebo-controlled trial in men aged 20-50 found that dutasteride 0.5 mg significantly increased hair count and improved hair growth at week 24 compared with both finasteride and placebo. Dutasteride has been found to be approximately three times more potent than finasteride in inhibiting type-1 5AR and 100 times more potent in inhibiting type-2 5AR.

    Beyond hair count increases, patients report improved scalp coverage, enhanced quality of life, and greater treatment satisfaction. The drug both prevents further loss and, in many cases, reverses miniaturization. Approximately 65-90% of patients experience stabilization of hair loss, while 48-77% show visible regrowth.

    The powder formulation offers additional benefits over commercial capsules. Compounded topical solutions may reduce systemic absorption and therefore systemic side effects, while allowing higher local concentrations at the follicular level. Microneedling combined with topical dutasteride has shown particular promise: one randomized study found that 52.9% of men receiving microneedling plus topical 0.01% dutasteride showed significant improvement at week 16, compared to 17.6% in the microneedling-saline control group.

    The optimal dosage of dutasteride for hair loss remains a subject of clinical debate, largely because the drug is used off-label and no standardized dosing protocol exists. The most common approach is 0.5 mg taken once daily-the same dose used for BPH. However, many physicians now advocate for less frequent dosing due to the drug's exceptionally long half-life.

    The International Society of Hair Restoration Surgeons reports that most physicians advise taking 0.5 mg twice weekly to achieve sufficient DHT reduction. Some practitioners recommend two or three times per week, which clinical experience suggests is usually adequate to see hair growth improvements. A small subset of patients may require daily dosing if they are poor responders to the intermittent regimen.

    For those utilizing dutasteride powder for compounding, precise measurement is critical. The powder must be weighed using an analytical balance accurate to 0.1 mg, as even small errors can significantly alter the delivered dose. For topical preparations, concentrations typically range from 0.01% to 0.1%, compounded with vehicles such as propylene glycol, ethanol, or commercial minoxidil solutions.

    Dutasteride is not a "cycle" drug in the sense of anabolic steroids or performance-enhancing substances. It is a chronic maintenance therapy-discontinuation leads to the gradual return of DHT to baseline levels and resumption of hair loss. However, the concept of a "cycle" is relevant in two contexts.

    First, a loading phase may be employed to accelerate the attainment of steady-state concentrations. Because of the drug's long half-life, it can take 90 to 120 days of continuous dosing to reach steady-state levels. Some clinicians recommend a brief daily loading period followed by transition to intermittent maintenance dosing. The steady-state concentration for a dose of 0.5 mg every fourth day is approximately 3.7 mg, requiring 15 consecutive daily doses to achieve.

    Second, visible results follow a predictable timeline. It typically takes three to six months before patients begin observing noticeable improvements. Scalp DHT reduction occurs more slowly than systemic reduction because the prostate absorbs dutasteride more rapidly than the scalp, owing to different vascular networks and enzyme densities. Maximum therapeutic effect may require up to one year of continuous therapy. This protracted timeline reflects both the pharmacokinetics of the drug and the biology of the hair growth cycle-hair follicles must complete multiple cycles of growth, regression, and rest before improvements become visually apparent.

    The half-life of dutasteride is its most distinctive pharmacokinetic property and the primary factor driving its dosing strategy. The plasma half-life is approximately five weeks-roughly 35 days. This compares to just six to eight hours for finasteride. In practical terms, this means that after a single 0.5 mg dose, half of the drug remains in the body five weeks later. After ten weeks, one-quarter remains. After fifteen weeks, one-eighth remains.

    The extended half-life arises from dutasteride's extraordinary affinity for plasma proteins, particularly albumin, to which it binds tightly and from which it releases only slowly. This protein binding creates a reservoir effect, maintaining therapeutic concentrations long after the last dose. Some sources report a half-life exceeding 240 hours (ten days), though the five-week figure (840 hours) is more widely cited in pharmacokinetic literature.

    This long half-life has several clinical implications. First, it permits intermittent dosing-taking the drug two or three times weekly is sufficient to maintain steady-state DHT suppression. Second, it means that any side effects that develop will persist for weeks or months after discontinuation, rather than resolving within days. Third, it necessitates a long washout period if a patient wishes to conceive or switch therapies. Fourth, it explains why the drug requires months to reach steady state and months more to produce visible effects.

    The term "post-cycle therapy" originates in the context of anabolic steroid use, where exogenous androgens suppress natural testosterone production and PCT is employed to restore endogenous hormone balance. Dutasteride does not suppress testosterone-in fact, it increases circulating testosterone by preventing its conversion to DHT. Therefore, conventional PCT as practiced in bodybuilding circles is irrelevant to dutasteride use.

    However, if one interprets "PCT" more broadly as "what happens when you stop taking the drug," several considerations arise. Because of the five-week half-life, dutasteride does not wash out quickly. Discontinuation leads to a gradual, not abrupt, return of DHT to baseline. This slow decline means patients do not experience a sudden "crash" or rebound effect. However, it also means that any androgenic side effects-such as decreased libido, erectile dysfunction, or mood changes-may persist for weeks to months after the last dose.

    For patients who discontinue due to side effects, the extended half-life is a double-edged sword: while it prevents sudden hormonal fluctuations, it also prolongs the duration of adverse effects. For patients who discontinue because they have achieved desired results, the slow washout means that hair benefits may persist for some time, but the underlying DHT-driven miniaturization will eventually resume as DHT levels normalize.

    Some clinicians advocate for a "taper" rather than abrupt cessation, though the pharmacokinetic rationale for tapering is weak given that the drug effectively tapers itself due to its long half-life. More relevant is the potential need for alternative DHT-blocking therapies if dutasteride is discontinued-patients may transition to finasteride or topical anti-androgens to maintain some degree of DHT suppression.

    For those who experience side effects and wish to accelerate recovery, no specific reversal agent exists. Management is supportive: monitoring until symptoms resolve, with the understanding that full resolution may take several months. In severe cases, consultation with an endocrinologist may be warranted.

    The side effect profile of dutasteride mirrors that of finasteride, though the extended half-life means adverse effects may be more persistent if they occur. The most commonly reported side effects include decreased libido, erectile dysfunction, ejaculatory disorders, gynecomastia (breast enlargement), fatigue, and mood disturbances including depression. These effects are dose-dependent and occur in a minority of patients-the majority tolerate the drug without significant adverse experiences.

    The risk of sexual side effects appears similar between dutasteride and finasteride, despite dutasteride's greater DHT suppression. This suggests that the relationship between DHT reduction and sexual function is not strictly linear-there may be a threshold below which further DHT suppression does not proportionally increase side effect risk.

    Long-term safety data are derived primarily from prostate studies, where patients took the drug for years. These studies have not identified major long-term safety concerns beyond the known side effect profile. However, the drug's effects on neurosteroid synthesis-5-alpha-reductase is involved in the production of certain neuroactive steroids-remain an area of ongoing investigation and concern for some patients.

Trade names	Loniten, Rogaine,2,4-Diamino-6-piperidinopyrimidine 3-oxide
CAS	38304-91-5
Molar mass	209.253
MF	C9H15N5O
Purity	Above 98%
Apprarance	White crystalline powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    Top-quality dutasteride powder represents one of the most potent pharmacological interventions available for androgenetic alopecia. Its dual inhibition of both 5-alpha-reductase isoforms achieves near-total DHT suppression-a level of efficacy that surpasses finasteride and places it at the apex of medical hair loss therapies. The powder formulation offers flexibility for compounding and topical administration, potentially mitigating systemic side effects while maintaining local efficacy.

    The drug's defining characteristic-its five-week half-life-shapes every aspect of its clinical use: dosing frequency, time to effect, persistence of side effects, and washout duration. This pharmacokinetic profile demands patience from patients (results require months to manifest) and caution from prescribers (side effects, if they occur, are not quickly reversible).

    For the appropriate patient-a man with documented androgenetic alopecia who has either failed finasteride or seeks maximal DHT suppression-dutasteride offers a powerful tool. It is not a cure, but a chronic management strategy: continuation is required to maintain benefits, and discontinuation leads to eventual reversal of gains. With proper patient selection, informed consent regarding the extended half-life and side effect profile, and realistic expectations about the timeline for results, dutasteride powder can be a transformative addition to the hair loss treatment armamentarium.

Hot Tags: top-quality dutasteride powder for hair loss cas:164656-23-9, China top-quality dutasteride powder for hair loss cas:164656-23-9 manufacturers, suppliers, factory, High quality Drostanolone Propionate, Methenolone Enanthate, Methyltestosterone, Oxymetholone, Testosterone Acetate, Testosterone Undecanoate Gonadotropin Secretion